Number of the records: 1
治療に使用するための、置換チェノピロロピリミジンリボヌクレオシド
- 1.0531686 - ÚOCHB 2021 RIV jpn P - Patent Document
Hocek, Michal - Tichý, Tomáš - Hajdúch, M. - Džubák, P.
治療に使用するための、置換チェノピロロピリミジンリボヌクレオシド.
[Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use.]
2020. Owner: Ústav organické chemie a biochemie AV ČR, v. v. i. - Univerzita Palackého v Olomouci. Date of the patent acceptance: 19.02.2020. Patent Number: JP6650074
R&D Projects: GA ČR(CZ) GA16-00178S; GA TA ČR(CZ) TE01020028; GA MZd(CZ) NV15-31984A
Institutional support: RVO:61388963
Keywords : nucleosides * fused heterocycles * cytostatics
OECD category: Medicinal chemistry
https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=JP&NR=6650074B2&KC=B2&FT=D&ND=4&date=20200219&DB=&locale=en_EP
本発明は、一般式Ｉの置換チエノピロロピリミジンリボヌクレオシドの新しい群を提供し、ここでＲは請求項で定義される。 本発明の化合物は、好ましくは様々な組織遺伝学的起源の腫瘍を含む広範囲の疾患の癌細胞株に対して、強力な細胞増殖抑制および細胞毒性活性を示す。
The invention provides a new group of substituted thienopyrrolopyrimidine ribonucleosides of general formula I, wherein R is defined in the claims. The compounds of this invention show strong cytostatic and cytotoxic activities preferably against cancer cell lines of broad spectrum of diseases including tumors of various histogenetic origin.
Permanent Link: http://hdl.handle.net/11104/0310303
Number of the records: 1